Clemence Martin
Overview
Explore the profile of Clemence Martin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
67
Citations
670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chouchana L, Collier M, Martin C, Burgel P, Treluyer J
J Cyst Fibros
. 2025 Mar;
PMID: 40058987
Objectives: Recent therapeutic advances, mainly with the advent of CFTR modulators, have been associated with an increasing number of pregnancies in females with cystic fibrosis (fwCF). This study aimed to...
2.
Pesenti L, de Oliveira Formiga R, Tamassia N, Gardiman E, Chable de La Heronniere F, Gasperini S, et al.
J Innate Immun
. 2025 Feb;
17(1):154-175.
PMID: 40015257
Introduction: Neutrophils are key players in the hyperinflammatory response during SARS-CoV-2 infection. The cytosolic proliferating cell nuclear antigen (PCNA) is a scaffolding protein highly dependent on the microenvironment status and...
3.
Teillaud J, Regard L, Martin C, Siberil S, Burgel P
Methods Mol Biol
. 2024 Nov;
2864:281-297.
PMID: 39527228
Animal models can be helpful tools for deciphering the generation, maintenance, and role of tertiary lymphoid structures (TLS) during infections or tumor development. We describe here the establishment of a...
4.
Fajac I, Burgel P, Martin C
Eur Respir Rev
. 2024 Sep;
33(173).
PMID: 39322262
Cystic fibrosis (CF) is a genetic disease caused by variants in the gene encoding for the CF transmembrane conductance regulator (CFTR) protein, a chloride and bicarbonate channel. CFTR dysfunction results...
5.
Burgel P, Sermet-Gaudelus I, Girodon E, Durieu I, Houdouin V, Audousset C, et al.
Lancet Respir Med
. 2024 Aug;
12(11):888-900.
PMID: 39151434
Background: Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration...
6.
Cassius De Linval Q, Barat M, Aissaoui M, Talabard M, Martin C, Malamut G, et al.
Insights Imaging
. 2024 Aug;
15(1):197.
PMID: 39112694
Thoracic manifestations of inflammatory bowel disease (IBD) are rare, occurring in less than 1% of patients. Unlike most other extra-intestinal manifestations, they predominate in patients with ulcerative colitis rather than...
7.
Burgel P, Paillasseur J, Durieu I, Reynaud-Gaubert M, Hamidfar R, Murris-Espin M, et al.
Ann Am Thorac Soc
. 2024 Apr;
21(7):1053-1064.
PMID: 38579175
Limited data exist on the safety and effectiveness of elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis (pwCF) and advanced lung disease. To evaluate the effects of ETI in an unselected...
8.
Cazier P, Chassagnon G, Dhote T, Da Silva J, Kanaan R, Honore I, et al.
Eur Respir J
. 2024 Feb;
63(3.
PMID: 38331460
Background: This study sought to evaluate the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on lung structural abnormalities in adults with cystic fibrosis (awCF) with a specific focus on the reversal of bronchial...
9.
Burgel P, Sermet-Gaudelus I, Girodon E, Kanaan R, Le Bihan J, Remus N, et al.
Eur Respir J
. 2024 Jan;
63(1).
PMID: 38242629
No abstract available.
10.
Burgel P, Southern K, Addy C, Battezzati A, Berry C, Bouchara J, et al.
J Cyst Fibros
. 2024 Jan;
23(2):187-202.
PMID: 38233247
This is the third in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF. This paper focuses on recognising...